Posts

Although Pfizer has dominated the headlines with Comirnaty, it’s not the only company that has created a COVID-19 vaccine using mRNA technology. The biotechnology company Moderna received FDA authorization for its own mRNA COVID-19 vaccine, Spikevax, in December 2021 for administration in individuals 18 years old and older.

The U.S. Equal Employment Opportunity Commission filed a lawsuit Monday against Eli Lilly and Co. alleging the company refused to hire older workers for sales representative positions.

A federal judge on Tuesday dismissed, for the second time, a whistleblower lawsuit accusing drugmaker Novartis AG of paying kickbacks to doctors through a sham speaker program to promote its multiple sclerosis drug Gilenya.

AstraZeneca Plc on Monday won the dismissal of a U.S. shareholder lawsuit claiming that it concealed problems in developing its COVID-19 vaccine, making it unlikely the treatment would win regulatory approval in the United States.

Johnson & Johnson (J&J) has reached a A$300 million ($204.90 million) settlement in two Australian class action suits filed by Shine Lawyers for selling defective pelvic mesh implants to Australian women, the law firm said on Monday.

Two U.S. military veterans on Thursday sued 3M Co. to block its planned spinoff of its healthcare business, which they called an illegal attempt to avoid compensating veterans for hearing damage caused by the company’s military-issue earplugs.

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic.

The company faces more than 3,000 lawsuits from state and local governments around the country over the drug. No final deal has been announced and AbbVie denies wrongdoing.

The whistleblower claim was brought by former employee Michael Bawduniak, who accused the company of paying off doctors to favor its multiple sclerosis drugs over those of its competitors. The trial for this case was scheduled to begin July 26.

A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co. of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought for $80.3 billion in 2019.